Compare Archer-Daniels-Midland Co (ADM) vs ADMA Biologics Inc (ADMA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs ADMA Biologics Inc — how do they compare? Archer-Daniels-Midland Co trades at $80.46 (market cap $38.79B), while ADMA Biologics Inc trades at $9.81 (market cap $2.18B). The key difference: Archer-Daniels-Midland Co is far larger — about 17.8× ADMA Biologics Inc's market cap, and Archer-Daniels-Midland Co pays a 2.58% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADM | ADMA | |
|---|---|---|
Market Cap | $38.79B | $2.18B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $20.38 |
52-Week Low | $56.00 | $7.60 |
Enterprise Value | $47.04B | $2.25B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $76.59, down 1.19% with a bearish technical signal despite recent earnings beats. The company raised its 2026 outlook after strong Q2 results driven by biofuels and crushing margins. Valuation appears reasonable with P/E of 20.93 and P/S of 0.45, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Analyst consensus is mixed with 33% buy ratings but a $88 price target suggesting 15% upside.
The stock offers value with solid dividends and improved cash flow, but faces execution risks and revenue pressure. Near-term catalysts include Q3 earnings and continued biofuels strength, while competitive pressures and margin compression remain concerns. The current price near support at $76 provides a potential entry point for long-term investors.
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →
